Loading...

Industry News

SynBioBeta brings you the latest news weekly to help you stay informed and learn about the latest developments in the synthetic biology industry. Subscribe to receive the latest news weekly to your inbox. Have news to share? Contact us to submit your story.

Subscribe

Stay Updated on the Latest News in Synthetic Biology

Subscribe to the Weekly SynBioBeta Digest
Subscribe

Latest News

March 2017

Lightning Talks at SynBioBeta London will Showcase International Synbio Scene

Cell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other Diseases

AgriMetis Announces Publication of Spinosyn Analog Patent Applications

DEINOVE now has a catalog of active extracts identified for cosmetic applications

How DARPA is Leading the Debate on Biosecurity and Biosafety With Genome Editors

Zio Fungicide, Developed by AgBiome, Receives EPA Registration

Synthego Announces Modified Synthetic sgRNA for CRISPR Genome Editing

Intrexon CEO RJ Kirk to Speak at SB7.0

eGenesis Co-Founder Luhan Yang Named Young Global Leader by World Economic Forum

eGenesis Announces $38 Million Series A Financing, Led by Biomatics Capital and ARCH Venture Partners, to Solve Shortage of Organs for Donation

Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

Evolva teams up with FCI to expand nootkatone and valencene sales & marketing in Europe

Thermo Fisher Scientific Announces First-Ever Cloud-Based Application for Connectivity to Electronic Pipettes

Synpromics Granted Key Patent in Synthetic Promoter Development

Eurofins Genomics US Announces Commercial Launch of Next Generation DNA Synthesis Service

BioBright Tools Bring ‘Superpowers’ to the Biology Lab

Lord David Prior of Brampton to Keynote SynBioBeta London

The Tools, Challenges, and Future Uses for Renewable Bio-based Materials

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte